Repository logo
 
Publication

Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy

2020-11Journal article Open access
Simple item page
dc.contributor.authorValentim Gonçalves, A
dc.contributor.authorPereira-da-Silva, T
dc.contributor.authorGalrinho, A
dc.contributor.authorRio, P
dc.contributor.authorSoares, RM
dc.contributor.authorFeliciano, J
dc.contributor.authorIlhão Moreira, R
dc.contributor.authorSilva, S
dc.contributor.authorAlves, S
dc.contributor.authorCapilé, E
dc.contributor.authorCruz Ferreira, R
dc.date.accessioned2020-12-15T15:59:55Z
dc.date.available2020-12-15T15:59:55Z
dc.date.issued2020-11
dc.description.abstractBackground: Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. Objective: This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. Methods: Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan therapy, expecting no additional HF treatment. CPET data were gathered in the week before and 6 months after sacubitril-valsartan therapy. Statistical differences with a p-value <0.05 were considered significant. Results: Out of 42 patients, 35 (83.3%) completed the 6-month follow-up, since 2 (4.8%) patients died and 5 (11.9%) discontinued treatment for adverse events. Mean age was 58.6±11.1 years. New York Heart Association class improved in 26 (74.3%) patients. Maximal oxygen uptake (VO2max) (14.4 vs. 18.3 ml/kg/min, p<0.001), VE/VCO2slope (36.7 vs. 31.1, p<0.001), and exercise duration (487.8 vs. 640.3 sec, p<0.001) also improved with sacubitril-valsartan. Benefit was maintained even with the 24/26 mg dose (13.5 vs. 19.2 ml/kg/min, p=0.018) of sacubitril-valsartan, as long as this was the highest tolerated dose. Conclusions: Sacubitril-valsartan therapy is associated with marked CPET improvement in VO2max, VE/VCO2slope, and exercise duration.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationArq Bras Cardiol. 2020 Nov;115(5):821-827.pt_PT
dc.identifier.doi10.36660/abc.20190443pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3533
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSociedade Brasileira de Cardiologiapt_PT
dc.subjectHSM CARpt_PT
dc.subjectAminobutyratespt_PT
dc.subjectAgedpt_PT
dc.subjectAngiotensin Receptor Antagonistspt_PT
dc.subjectDrug Combinationspt_PT
dc.subjectHeart Failure / drug therapypt_PT
dc.subjectHumanspt_PT
dc.subjectMiddle Agedpt_PT
dc.subjectProspective Studies
dc.subjectOxygen
dc.subjectStroke Volume
dc.subjectTetrazoles
dc.subjectTreatment Outcome
dc.subjectVentricular Function, Left
dc.titleMaximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapypt_PT
dc.title.alternativeMelhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartanapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage827pt_PT
oaire.citation.issue5pt_PT
oaire.citation.startPage821pt_PT
oaire.citation.titleArquivos Basileiros de Cardiologiapt_PT
oaire.citation.volume115pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Arq Bras Cardiol 2020 maximal.pdf
Size:
305.17 KB
Format:
Adobe Portable Document Format
Download

Collections

CAR - Artigos